Join us for the third webinar in the ASTCT 2022 CAR T Webinar Series titled, 'Off the Shelf CAR T: a deep dive'. Drs. Matt Cooper and Swami Iyer will identify available off the shelf CAR T products, review the cell types used, and review the clinical, preclinical data, unique constructs and place in therapy of off the shelf CAR T products. Following their presentations, the session will move into a panel discussion facilitated by Dr. Laurie Davis. 

Moderator:

Dr. Laurie Davis; Assistant Professor of Pediatrics, Children's Hospital of San Antonio

Faculty:

Dr. Matt Cooper; Co-Founder & Chief Scientific Officer at WUGEN and Assistant Professor of Medicine at Washington University School of Medicine

Dr. Swaminathan Iyer; Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

On Friday, September 9, 2022, ASTCT is hosting the second webinar in its 2022 CAR T Webinar Series. Join Drs. Eric Smith and Michael Jain as they review data and strategies to prevent relapse post CAR T, review current CAR T outcomes, and discuss possible published and proposed treatment strategies for CAR T relapse. Dr. Smith's presentation will focus on myeloma, and Dr. Jain's will focus on lymphoma. After their presentations, both speakers will answer questions from the audience. 

Moderator:

Dr. Mariana Lucena; Medexus Pharma

Faculty:

Dr. Eric Smith; Director of Translational Research (Immune Effector Cell Therapies) at Dana-Farber Cancer Institute and Assistant Professor of Medicine, Harvard Medical School 

Dr. Michael Jain; Assistant Member of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center

After the success of the 2021 CAR T Webinar Series, ASTCT is excited to announce another six-part CAR T Webinar Series sponsored by Johnson & Johnson for 2022!

To kick off the series, join us on August 25 at 1 PM CDT for the first session, ‘CAR T Manufacturing.’ In this hour-long webinar, Dr. Megan Davis, Dr. Andrew Timmons, and Dr. Boro Dropulić will give presentations on aspects of local manufacturing, an overview of navigating regulation in gene and cell therapy, and the challenges and opportunities of manufacturing clinical grade vectors for CAR T cell therapy. After their presentations, Drs. Davis, Timmons, and Dropulić will field audience questions and engage in a panel discussion. 

Moderator:

Dr. Armin Ghobadi; Associate Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine

Faculty:

Dr. Megan (Suhoski) Davis; Director, Product Development Laboratory, University of Pennsylvania

Dr. Andrew Timmons; Biologist, Office of Tissues and Advanced Therapies, Division of Cellular & Gene Therapies, US Food and Drug Administration

Dr. Boro Dropulić; Executive Director, Caring Cross

ASTCT has been in talks with the White House and CDC regarding national supply and demand concerns with Evusheld. There is a large supply available, but the supply is underutilized. This webinar will provide broader education to ASTCT members to spread awareness about Evusheld, including understanding how and when to use Evusheld in regards to vaccines with transplant patients.

Moderator:

Dr. Zenia Papanicolaou, MD

Memorial Sloan Kettering Cancer Center

Faculty:

Dr. Dianna Howard, MD

Professor, Hematology and Oncology

Atrium Health, Wake Forest Baptist

Dr. Aliyah Baluch, MD, MSc, FACP, FIDSA

Associate Professor, Department of Oncologic Services

Moffitt Cancer Center

Alycia Maloney

ASTCT Director of Government Relations

White House/CDC Representatives:

Erin Abramsohn

Emily Koumans

Melisa Shah

Thomas Tsai

This activity is the third in a series of four educational activities on treating relapsed/refractory Ph- acute lymphocytic leukemia. Dr. Ayman Qasrawi from the University of Kentucky Markey Cancer Center, discusses treatment options and outcomes. He introduces a case study highlighting the treatment decisions in a patient with relapsed Ph – ALL.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Identify patients who could benefit from CD22-directed ADC therapy using current practice guideline recommendations

Faculty:

Ayman Qaswari, MD

Assistant Professor

Division of Hematology & BMT

University of Kentucky

Lexington, KY

Content Reviewers:

Kirsten Roblee, MHI, BSN, RN, OCN 

Administrative Nurse Manager, Oncology Infusion Services

Dublin Methodist Hospital & Grady Memorial Hospital

Ohio Health

Columbus, OH

METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT

Technical Requirements: http://www.francefoundation.co...

• There are no fees for participating in and receiving credit for this activity
• Review the activity objectives and CME/CE information
• Complete the CME/CE activity
• Complete the online posttest. A score of at least 80% is required to successfully complete this activity. The participant may take the test until successfully passed.
• Complete the CME/CE evaluation/attestation form. This form provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.

Credit documentation/reporting:

• If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download

ACCREDITED PROVIDER 

This activity is provided by The France Foundation. This activity was produced in collaboration with American Society for Transplantation and Cellular Therapy.

TARGET AUDIENCE

The target audience for this initiative includes hematology/oncology physicians and other members of the multidisciplinary cancer care team involved in the management of patients with acute lymphocytic leukemia.

STATEMENT OF NEED

Acute lymphocytic leukemia (ALL) is a heterogeneous malignancy of B or T lymphoblasts characterized by uncontrolled proliferation of abnormal, immature lymphocytes and their progenitors, which ultimately leads to crowding of bone marrow elements and other lymphoid organs.[i] While complete remission has improved over the past decades, almost 50% of adult patients will relapse.[ii] Prognosis for patients with relapsed or refractory (R/R) ALL is poor.[iii]

A number of treatments have been approved for and are in use for ALL, including chemotherapy, radiotherapy, and targeted therapy. Antibody-drug conjugate therapy directed against CD22 with inotuzumab ozogamicin (InO) has been shown in trials to be an effective tool to manage R/R Philadelphia chromosome positive or negative B-cell ALL, but it can be associated with venoocclusive disease (VOD), particularly manifesting in the liver as sinusoidal obstruction syndrome.[iv] The risk of VOD can be higher after hematopoietic stem cell transplantation (HSCT), particularly after certain conditioning regimens, but it is also possible without HSCT.⁴

Given that InO is effective, it is important that clinicians have the confidence to use it. Confidence can be improved with education, so clinicians are more familiar with this therapy, its place in guidelines, its adverse events, and how to manage them.

ACCREDITATION STATEMENT  

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the American Society for Transplantation and Cellular Therapy. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

Physicians

The France Foundation designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

DISCLOSURE POLICY

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs.

Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Disclosures

The following financial relationships have been disclosed:

DISCLOSURE OF UNLABELED USE

TFF and ASTCT require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is supported by an educational grant from Pfizer.

DISCLAIMER

The France Foundation (TFF) and the American Society for Transplantation and Cellular Therapy (ASTCT) present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. TFF, ASTCT, and the commercial supporter(s) assume no liability for the information herein.

COPYRIGHT INFORMATION 

 Copyright © 2022 The France Foundation and The American Society for Transplantation and Cellular Therapy. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.

• Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without The France Foundation's prior written permission

PRIVACY POLICY

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except when such information is required for reporting purposes to the ACCME. The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you. Additional information regarding The France Foundation’s Privacy Policy can be viewed at http://www.francefoundation.co.... 

CONTACT INFORMATION

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

 REFERENCES:

[i] Puckett Y, Chan O. Acute lymphocytic leukemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; June 29, 2021. https://pubmed.ncbi.nlm.nih.gov/29083572

[ii] Relapse in Acute Lymphoblastic Leukaemia (ALL). Leukemia Care. 2019. Accessed September 13, 2021. https://media.leukaemiacare.org.uk/wp-content/uploads/Relapse-in-Acute-Lymphoblastic-Leukaemia-ALL-Web-Version.pdf

[iii] DeAngelo DJ, Advani AS, Marks DI, et al. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer J. 2020;10(8):81. https://pubmed.ncbi.nlm.nih.gov/32769965

[iv] Kebriaei P, Cutler C, de Lima M, et al. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018;53(4):449-456. https://pubmed.ncbi.nlm.nih.gov/29330398

This activity is the second in a series of four modules on relapsed/refractory acute lymphocytic leukemia (ALL). Module 2 focuses on treatment of Ph+ Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL). This module is presented by Dr. Jessica Leonard from Oregon Health & Sciences University Knight Cancer Institute.

Please review this information, and proceed below

Learning Objectives

Upon completion of the activity, participants should be able to:

• Identify patients who could benefit from CD22-directed ADC therapy using current practice guideline recommendations
• Develop strategies to prevent, monitor, and manage VOD associated with CD22-directed ADC therapy 

FACULTY

Jessica Leonard, MD

Assistant Professor of Medicine

Division of Hematology/Medical Oncology

Oregon Health & Science University

Knight Cancer Institute

Portland, OR

Kirsten Roblee, MHI, BSN, RN, OCN 

Administrative Nurse Manager, Oncology Infusion Services

Dublin Methodist Hospital & Grady Memorial Hospital

Ohio Health

Columbus, OH

METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT

Technical Requirements: http://www.francefoundation.co...

• There are no fees for participating in and receiving credit for this activity
• Review the activity objectives and CME/CE information
• Complete the CME/CE activity
• Complete the online posttest. A score of at least 80% is required to successfully complete this activity. The participant may take the test until successfully passed.
• Complete the CME/CE evaluation/attestation form. This form provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.

Credit documentation/reporting:

• If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download

ACCREDITED PROVIDER 

This activity is provided by The France Foundation. This activity was produced in collaboration with American Society for Transplantation and Cellular Therapy.

TARGET AUDIENCE

The target audience for this initiative includes hematology/oncology physicians, nurse practitioners, nurses, and other members of the multidisciplinary cancer care team involved in the management of patients with acute lymphocytic leukemia.

STATEMENT OF NEED

Acute lymphocytic leukemia (ALL) is a heterogeneous malignancy of B or T lymphoblasts characterized by uncontrolled proliferation of abnormal, immature lymphocytes and their progenitors, which ultimately leads to crowding of bone marrow elements and other lymphoid organs.[i] While complete remission has improved over the past decades, almost 50% of adult patients will relapse.[ii] Prognosis for patients with relapsed or refractory (R/R) ALL is poor.[iii]

A number of treatments have been approved for and are in use for ALL, including chemotherapy, radiotherapy, and targeted therapy. Antibody-drug conjugate (ADC) therapy directed against CD22 with inotuzumab ozogamicin (InO) has been shown in trials to be an effective tool to manage R/R Philadelphia chromosome positive (Ph+) or negative (Ph–) B-cell ALL. However, it can be associated with venoocclusive disease (VOD), particularly manifesting in the liver as sinusoidal obstruction syndrome (SOS).[iv] The risk of VOD can be higher after hematopoietic stem cell transplantation (HSCT), particularly after certain conditioning regimens, but is also possible without HSCT.⁴

Given that InO is effective, it is important that clinicians have the confidence to use it. Confidence can be improved with education, so clinicians are more familiar with this therapy, its place in guidelines, its adverse events (AEs), and how to manage them.

ACCREDITATION STATEMENT  

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the American Society for Transplantation and Cellular Therapy. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

Physicians

The France Foundation designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

DISCLOSURE POLICY

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs.

Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

The following financial relationships have been disclosed:

DISCLOSURE OF UNLABELED USE

TFF and ASTCT require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is supported by educational grant from Pfizer.

DISCLAIMER

The France Foundation (TFF) and the American Society for Transplantation and Cellular Therapy (ASTCT) present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. TFF, ASTCT, and the commercial supporter(s) assume no liability for the information herein.

COPYRIGHT INFORMATION

Copyright © 2022 The France Foundation and The American Society for Transplantation and Cellular Therapy. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.

• Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without The France Foundation's prior written permission

PRIVACY POLICY

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except when such information is required for reporting purposes to the ACCME. The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you. Additional information regarding The France Foundation’s Privacy Policy can be viewed at http://www.francefoundation.co....

 CONTACT INFORMATION

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

References:

[i] Puckett Y, Chan O. Acute lymphocytic leukemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; June 29, 2021. https://pubmed.ncbi.nlm.nih.gov/29083572

[ii] Relapse in Acute Lymphoblastic Leukaemia (ALL). Leukemia Care. 2019. Accessed September 13, 2021. https://media.leukaemiacare.org.uk/wp-content/uploads/Relapse-in-Acute-Lymphoblastic-Leukaemia-ALL-Web-Version.pdf

[iii] DeAngelo DJ, Advani AS, Marks DI, et al. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer J. 2020;10(8):81. https://pubmed.ncbi.nlm.nih.gov/32769965

[iv] Kebriaei P, Cutler C, de Lima M, et al. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018;53(4):449-456. https://pubmed.ncbi.nlm.nih.gov/29330398

Title: CD19 Directed Therapy Debate: Blinatumomab vs. CD19 Chimeric Antigen Receptor T-cells (CAR-T) for Acute Lymphoblastic Leukemia (ALL)

Speakers: Anthony J. Perissinotti, PharmD, BCOP and Bernard Lawrence Marini, PharmD, BCOP

This session was originally presented at the 2022 Tandem Meetings Pharmacist Conference.

Learning Objectives: 

• Review key background information in the treatment of acute lymphoblastic leukemia (ALL)
• Appraise the literature surrounding the use of blinatumomab and chimeric antigen receptor T-cell (CAR-T) therapy in the treatment of ALL 
• Defend the use of either blinatumomab or CAR-T given a patient scenario 
• Compare and contrast major toxicities of blinatumomab and CAR-T, including financial toxicity

This session has been accredited for 1 hour of BCOP Credit by HOPA. In order to claim BCOP credit, learners must view the presentation in its entirety and pass the quiz with a minimum score of 80%. You will only have two attempts to pass the quiz.

Title: Hematopoietic Stem Cell Transplantation for Inherited Bone Marrow Failure Syndromes

Speaker: Binni Kunvarjee, PharmD, BCOP

This session was originally presented at the 2022 Tandem Meetings Pharmacist Conference.

Learning Objectives: 

• Describe the genetic and phenotypic characteristics of various inherited bone marrow failure syndromes (IBMFS) in pediatric patients.
• Explain the role of hematopoietic stem cell transplantation (HCT) in treatment of the hematologic manifestations of IBMFS.
• Review available literature on impact of conditioning regimen, graft manipulation, and donor source on outcomes with HCT for IBMFS.
• Identify the disease-specific pre- and post-transplant considerations in patients receiving HCT for IBMFS.

This session has been accredited for 1 hour of BCOP Credit by HOPA. In order to claim BCOP credit, learners must view the presentation in its entirety and pass the quiz with a minimum score of 80%. You will only have two attempts to pass the quiz.

This workshop comprised short talks by representatives of ASTCT’s six international partner organizations on the subject of access to transplant across the world. Members from APBMT (Asia Pacific Blood and Marrow Transplantation Group); SBTMO (Sociedade Brasileira de Transplante de Medula Óssea); EBMT (European Blood and Marrow Transplantation); ANZTCT (Australia New Zealand Transplantation and Cellular Therapy Group); LABMT (Latin American Blood and Marrow Transplantation Group); and ISTCT (Indian Society for Transplantation and Cellular Therapy) presented on various aspects of access to transplant in their respective regions, such as conflict resolution, workforce development, standardization of processes, and health equity. 

The ASTCT Pharmacy SIG May 2022 Journal Club aired on May 11, 2022. This webinar consists of two, 30-minute journal club presentations, which include 20 min for presentation and 10 min for discussion/Q and A.

Presenters & Articles

Arthur Nguyen, PharmD 

PGY2 Oncology Resident, Oregon Health and Science University

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Elizabeth A. Meszaros, PharmD 

PGY2 Hematology/Oncology Pharmacy Resident, South Texas Veterans Healthcare System

Posttransplant Cyclophosphamide for Prevention of Graft-versus-Host Disease: The Prospective Randomized HOVON-96 Trial

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

1. Evaluate the safety and efficacy of Axicabtagene Ciloleucel for the treatment of large B-cell lymphomas (LBCL).
2. Review current standards of care for Graft-versus-Host Disease (GVHD) prevention for Matched Related Donors (MRD) and Matched Unrelated Donor (MUD) peripheral blood allogeneic hematopoietic stem cell transplants (alloHSCT).
3. Evaluate the utility of post-transplant cyclophosphamide (PTCy) combined with a short course of cyclosporine (CsA) as compared to mycophenolic acid (MPA) with CsA for GVHD prophylaxis in patients receiving MRD and MUD peripheral blood alloHSCT.

The France Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education and will award 1.0 CEU to pharmacists who complete the activity, complete the registration and evaluation forms, and successfully pass a posttest (>75%). There is no fee to participate in this activity. This is a knowledge-based educational activity. Your CE credits will be submitted electronically to the CPE Monitor. CE providers must upload participant information within 60 days from the date the participant completed the activity. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. 

Full CE information, including presenter disclosures and accreditation information, can be found in the Handouts tab or directly downloaded by clicking here.